OncoMatch/Clinical Trials/NCT06385730
Neoadjuvant PD-1 Blockade for Elderly Esophageal Squamous Cell Carcinoma (BLESS)
Is NCT06385730 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including neoadjuvant anti-PD-1 and neoadjuvant anti-PD-1 with LDRT for esophageal cancer.
Treatment: neoadjuvant anti-PD-1 · neoadjuvant anti-PD-1 with LDRT — The investigators will conduct a prospective phase 2 study to evaluate the efficacy and safety of neoadjuvant PD-1 blockade monotherapy with toripalimab in elderly patients with locally advanced resectable esophageal squamous cell carcinoma (ESCC).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Esophageal Carcinoma
Disease stage
Required: Stage T1N1-3M0, T2-3N0-3M0
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: radiotherapy
Have not received any anti-tumor treatment for esophageal cancer in the past, including radiotherapy, chemotherapy, surgery, etc.
Cannot have received: chemotherapy
Have not received any anti-tumor treatment for esophageal cancer in the past, including radiotherapy, chemotherapy, surgery, etc.
Cannot have received: surgery
Have not received any anti-tumor treatment for esophageal cancer in the past, including radiotherapy, chemotherapy, surgery, etc.
Cannot have received: immunotherapy
anti-tumor interventions such as radiotherapy, chemotherapy, immunotherapy or other medications
Lab requirements
Blood counts
NE ≥ 1.5×10^9/L; PLT ≥ 100×10^9/L; HGB ≥ 90 g/L
Kidney function
sCr ≤ 1.5×ULN or CrCl ≥ 50 mL/min (Cocheroft-Gault)
Liver function
bilirubin ≤ 1.5×ULN; ALT ≤ 2.5×ULN; AST ≤ 2.5×ULN
Blood routine: NE≥1.5×10^9/L; PLT≥100×10^9/L; HGB≥90 g/L; bilirubin≤ 1.5×ULN; ALT≤2.5×ULN; AST≤2.5×ULN; sCr≤1.5×ULN or CrCl≥50 mL/min（Cocheroft-Gault); INR≤1.5
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06385730 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage T1N1-3M0 or T2-3N0-3M0 is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages